The first report of immunomodulation after NTP was in an in vivo model of colorectal tumors, in which treatment promoted the release of damage-associated molecular patterns (DAMPs), subsequent infiltration of APCs into the tumor site, and activated tumor-specific CD8+ T cells [255]. The gene discussed is CD8A; the disease is neoplasm.